News Column

Researchers at Federal University Target Bacterial Infections (Exploring N-Acylhydrazone Derivatives Against Clinical Resistant Bacterial Strains)

September 5, 2014



By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Bacterial Infections. According to news reporting out of Rio de Janeiro, Brazil, by NewsRx editors, research stated, "Bacterial multiresistance is a health problem worldwide that demands new antimicrobials for treating bacterial-related infections. In this study, we evaluated the antimicrobial activity and the theoretical toxicology profile of N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazide derivatives against gram-positive and gram-negative bacteria clinical strains."

Our news journalists obtained a quote from the research from Federal University, "On that purpose we determined the minimum inhibitory (MIC) and bactericidal (MBC) concentrations, the in vitro cytotoxicity, and in silico risk profiles, also comparing with antimicrobial agents of clinical use. Among the 16 derivatives analyzed, four nitrofurans (N-H-FUR-NO2, N-Br-FUR-NO2, N-F-FUR-NO2, N-Cl-FUR-NO2) showed promising MIC and MBC values (MIC = MBC = 1-16 mu g/mL). The experimental data revealed the potential of these derivatives, which were comparable to the current antimicrobials with similar bactericidal and bacteriostatic profiles. Therefore, these molecules may be feasible options to be explored for treating infections caused by multiresistant strains. Our in vitro and in silico toxicity reinforced these results as these derivatives presented low cytotoxicity against human macrophages and low theoretical risk profile for irritant and reproductive effects compared to the current antimicrobials (e.g., vancomycin and ciprofloxacin). The molecular modeling analysis also revealed positive values for their theoretical druglikeness and drugscore."

According to the news editors, the research concluded: "The presence of a 5-nitro-2-furfur-2-yl group seems to be essential for the antimicrobial activity, which pointed these acylhydrazone derivatives as promising for designing more potent and safer compounds."

For more information on this research see: Exploring N-Acylhydrazone Derivatives Against Clinical Resistant Bacterial Strains. Current Microbiology, 2014;69(3):357-364. Current Microbiology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Current Microbiology - www.springerlink.com/content/0343-8651/)

Our news journalists report that additional information may be obtained by contacting A.C. Lannes, Federal University of Fluminense, Programa Posgrad Quim IQ, Rio De Janeiro, Brazil. Additional authors for this research include B. Leal, J.S. Novais, V. Lione, G. Monteiro, A.L. Lourenco, P.C. Sathler, A.K. Jordao, C.R. Rodrigues, L.M. Cabral, A.C. Cunha, V. Campos, V.F. Ferreira, M. de Souza, D.O. Santos and H.C. Castro (see also Bacterial Infections).

Keywords for this news article include: Antimicrobials, Brazil, Therapy, South America, Rio de Janeiro, Bacterial Infections and Mycoses

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Drug Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters